ASSOCIATION FOR ACCESSIBLE MEDICINES

Lobbying for ASSOCIATION FOR ACCESSIBLE MEDICINES

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$1,150,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 11

Centers For Medicare and Medicaid Services (CMS)
Commerce, Dept of (DOC)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Natl Economic Council (NEC)
Office of Management & Budget (OMB)
SENATE
U.S. Customs & Border Protection
U.S. Trade Representative (USTR)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 25

HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
S 2296
National Defense Authorization Act for Fiscal Year 2026
S 1071
National Defense Authorization Act for Fiscal Year 2026
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
HR 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application subm…
HR 4191
MAPS Act
S 1784
MAPS Act
HR 4132
Prescription Information Modernization Act of 2025
S 2027
Prescription Information Modernization Act of 2025
S 1414
Expedited Access to Biosimilars Act
S 3469
BIOSECURE Act of 2025
HR 3160
PREVAIL Act
S 1553
PREVAIL Act
HR 3152
Patent Eligibility Restoration Act of 2025
S 1546
Patent Eligibility Restoration Act of 2025
HR 3269
ETHIC Act
S 2276
ETHIC Act
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
HR 6485
Skinny Labels, Big Savings Act
S 43
Skinny Labels, Big Savings Act
S 1040
Drug Competition Enhancement Act
HR 5811
Restoring America’s Leadership in Innovation Act of 2025

Lobbying activity 5

Pharmacy

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in the Senate NDAA, S.2296 - National Defense Authorization Act for Fiscal Year 2026. S.1071 - National Defense Authorization Act for Fiscal Year 2026. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. Establishment Inspection Reports. S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469 - BIOSECURE Act of 2025. Quotas on Controlled Substances.

Medicare/Medicaid

Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation.

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act).

Trade (domestic/foreign)

General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Quotas on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. India Trade Negotiations. United States-Mexico-Canada Agreement.

Budget/Appropriations

FDA Funding.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.